About Us
Get winning Stock, Option and Cryptocurrency trade ideas from pro-traders. Follow their strategies, see how they perform.
|
|
|
ALNY - Alnylam Pharmaceutic...| Previous Close | $166.75 | Open | $165.78 |
| Volume | 535K | Market Cap | 19.373B |
| Yield | Last Dividend |
| Alnylam Pharmaceuticals, Inc. (NASDAQ:AL... | 01/16/21 |
| Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) EVP Laurie Keating sold 14,941 shares of the company???s stock in a transaction on Tuesday, January 12th. ... | |
| Alnylam Pharmaceuticals : Launches ??? P... | 01/10/21 |
| ??? New 5-Year Strategy Represents Alnylam???s Commitment to Delivering Transformative Rare and Prevalent Disease Medicines for Patients Around the Wo... | |
| Alnylam Launches ???Alnylam P5x25??? Str... | 01/10/21 |
| CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced its new 5-year... | |
| Berenberg Bank Stick to Their Hold Ratin... | 01/08/21 |
| Berenberg Bank Stick to Their Hold Rating for Alnylam Pharmaceuticals | |
| Needham Stick to Their Buy Rating for Al... | 01/07/21 |
| Needham Stick to Their Buy Rating for Alnylam Pharmaceuticals | |
| Alnylam Reports Positive Topline Results... | 01/07/21 |
| CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that the HELIO... | |
| Alnylam to Webcast Presentation at 39th ... | 01/04/21 |
| Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview a | |
| Global Antisense and RNAi Therapeutics M... | 12/31/20 |
| The forecast period 2020-2027 is going to be great for the Antisense and RNAi Therapeutics market which will be the face changer for Pharmaceutical in... | |
| Sage Therapeutics Announces the Appointm... | 12/16/20 |
| CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $SAGE #Sage--Sage Therapeutics (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapi... | |
| Alnylam Announces 2021 Product and Pipel... | 12/15/20 |
| CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, is kicking off a virtual R&D D... | |
| Alnylam to Webcast Virtual R&D Day | 12/08/20 |
| CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will w... | |
| Alnylam Issues 2nd Annual Patient Access... | 12/07/20 |
| CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today published two new report... | |
| Alnylam Completes Enrollment in ILLUMINA... | 12/03/20 |
| CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it has ac... | |
| The Week Ahead In Biotech: Hematology Co... | 11/29/20 |
| Biotech stocks had a rather uneventful week, as the sector was seen mostly flatlining amid light trading volume ahead of the Thanksgiving holiday. The... | |
| Attention Biotech Investors: Mark Your C... | 11/28/20 |
| The U.S. Food and Drug Administration's approval machinery churned out a lot of disappointments in November. Most of the negative verdicts were tied t... | |
| STAT+: Alnylam wins FDA approval for fir... | 11/24/20 |
| Alnylam Pharmaceuticals scored its third approval from the US Food and Drug Administration in as many years this week. | |
| Why These 3 Pharma Stocks Are Moving Tod... | 11/24/20 |
| Alnylam Pharmaceuticals (NASDAQ: ALNY) shares are trading higher on Tuesday after the company announced its OXLUMO injection has received FDA approval... | |
| Alnylam Announces Innovative Value-Based... | 11/24/20 |
| CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today a new framewor... | |
| Alnylam Announces U.S. Food and Drug Adm... | 11/24/20 |
| CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), the leading RNAi therapeutics company, announced today that the U.S. F... | |
| Alnylam Receives Approval for OXLUMO??? ... | 11/19/20 |
| CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that the Europ... | |
| U.S. Transthyretin Amyloidosis Treatment... | 11/17/20 |
| Industrial Growth Forecast Report U.S. Transthyretin Amyloidosis Treatment Market 2020-2027: The Global U.S. Transthyretin Amyloidosis Treatment Marke... | |
| Alnylam Reports Positive Interim Results... | 11/13/20 |
| CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today positive inter... | |
| Alnylam Pharmaceuticals Analysts Estimat... | 11/05/20 |
| Alnylam Pharmaceuticals announce their quarterly, annual earnings. See the latest EPS estimates. Listen to the conference call and remind yourself by?... | |
| Alnylam Pharmaceuticals Reports Third Qu... | 11/05/20 |
| CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today reported its consolidate... | |
| Alnylam to Webcast Presentations at Upco... | 11/02/20 |
| CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that managemen... | |
| Alnylam Wins Prestigious Prix Galien Awa... | 10/30/20 |
| CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced it has won the... | |
| Alnylam Named a Top Biopharma Employer b... | 10/29/20 |
| Share this Stock InformationCAMBRIDGE, Mass.???(BUSINESS WIRE)???Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, ... | |
| BidaskClub Downgrades Alnylam Pharmaceut... | 10/23/20 |
| Alnylam Pharmaceuticals (NASDAQ:ALNY) was downgraded by equities researchers at BidaskClub from a ???hold??? rating to a ???sell??? rating in a note i... | |
| Alnylam to Webcast Conference Call Discu... | 10/22/20 |
| CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will r... | |
| Buy rating | 11/25/20 |
| SVB Leerink maintains Market Perform rating and raises Price Target from $91.00 to $93.00 | |
| Strong Buy rating | 11/25/20 |
| Morgan Stanley maintains Overweight rating and raises Price Target from $200.00 to $203.00 | |
| Buy rating | 11/24/20 |
| SVB Leerink maintains Market Perform rating and raises Price Target from $90.00 to $91.00 | |
| Strong Buy rating | 11/06/20 |
| Morgan Stanley maintains Overweight rating and raises Price Target from $197.00 to $200.00 | |
| Date | 2020-11-05 (BMO) | Est. (EPS/Rev.) | ($1.66)/ 120.75M |
| Actual (EPS/Rev.) | $-1.58/ $125.85 M | EPS (TTM) | 0 |
| Total Revenue | $1.3B | Total Liabilities | $2.1B |
| Cost of Revenue | $2.5B | Total cash flow | $3.2 |
| Total Assets | $29.98B |
| % Insider | 12.52% | % Institutional | 76.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Service Name | Trader | % Success | |
|---|---|---|---|
| Tech and Bio Swing Trades | Matthew Burdeshaw | 46.00 % | Subscribe |
Get winning Stock, Option and Cryptocurrency trade ideas from pro-traders. Follow their strategies, see how they perform.
We are not a registered investment advisor. All investments involve risk, individual's trading does not guarantee future results or returns. Investors are fully responsible for any investment decisions they make. References to specific securities should not be construed as a recommendation to buy or sell that security only mentioned for informational purposes.
